|
Zepbound Outperforms Wegovy in Head-to-Head Obesity Trial
|
Written by: J. Smith |
Hits: 816
|
|
Large U.S. Study Finds No Increased Risk of Vision Loss from Semaglutide
|
Written by: J. Smith |
Hits: 770
|
|
CVS Shifts to Wegovy as Preferred Obesity Medication, Raising Questions About Access and Affordability
|
Written by: J. Smith |
Hits: 1420
|
|
Lilly’s Oral GLP-1 Pill Shows Strong Phase 3 Results as Novo Submits Rival for FDA Approval
|
Written by: J. Smith |
Hits: 1257
|
|
Lilly’s Oral GLP-1 Clears Key Trial as Pfizer Exits Race
|
Written by: J. Smith |
Hits: 718
|
|
FDA and Novo Nordisk Warn of Counterfeit Ozempic in U.S. Supply Chain
|
Written by: J. Smith |
Hits: 840
|
|
Liraglutide Reduces BMI in Children Under 12 With Obesity, But Questions Remain
|
Written by: J. Smith |
Hits: 750
|
|
Dexcom G7 15-Day CGM Wins FDA Clearance
|
Written by: J. Smith |
Hits: 1520
|
|
Rybelsus® Cuts Cardiovascular Risk by 14% in SOUL Trial
|
Written by: J. Smith |
Hits: 1101
|
|
Ozempic® Shows New Benefit for People with Type 2 Diabetes and PAD
|
Written by: J. Smith |
Hits: 1376
|
